Key result
Microvascular disease-related metabolites in hyperglycemia are linked to greater cardiac dysfunction and incident heart failure.
Its licence doesn't allow us to show a copy here.
Why the study?
Hyperglycemic states are associated with heart failure risk, but distinct metabolites linked to subclinical cardiac dysfunction in hyperglycemic versus euglycemic individuals are not well characterized.
Are specific metabolites associated with subclinical cardiac dysfunction and incident heart failure in hyperglycemic versus euglycemic individuals?
Observational (n=7,659)
Yes
Are specific metabolites associated with subclinical cardiac dysfunction and incident heart failure in hyperglycemic versus euglycemic individuals?
Effect estimate: HR range 1-1.9 and 1.1-2.9
Microvascular disease-related metabolites are associated with subclinical cardiac dysfunction and incident heart failure specifically in hyperglycemic individuals, supporting the role of microvascular dysfunction in diabetic heart failure pathogenesis.
Metabolite associations may flag HF risk in hyperglycemia; leaves open causal role and biomarker utility pending trials.
OBJECTIVE: Hyperglycemic states (prediabetes and diabetes) are associated with heart failure (HF) risk. We aimed to identify distinct metabolites for subclinical cardiac dysfunction, a precursor of HF, in hyperglycemic or euglycemic individuals. RESEARCH DESIGN AND METHODS: We conducted cross-sectional and prospective analyses of 2,492 HF-free participants from the Atherosclerosis Risk in Communities (ARIC) study visit 5, 2011-2013. A total of 1,297 participants were hyperglycemic (assessed on the basis of hemoglobin A1c >5.7%, fasting glucose >100 mg/dL, use of diabetes medication, or diagnosis), and 1,195 were euglycemic. We used logistic regression for analysis of association between 790 metabolites and cardiac dysfunction, defined according to echocardiographic abnormalities (left ventricular hypertrophy, systolic or diastolic dysfunction) or elevated NT-proBNP or troponin T, in two glycemic groups separately. We used Cox regression for prospective association between cardiac dysfunction-related metabolites identified in the prior step and HF risk, adjusting for clinical risk factors. Analyses were replicated in the Hispanic Community Health Study/Study of Latinos (HCHS/SOL) (n = 5,167). RESULTS: Microvascular disease-related metabolites (e.g., pseudouridine, N6-carbamoylthreonyladenosine, N6-acetyllysine, N2,N5-diacetylornithine) were associated with cardiac dysfunction in hyperglycemic individuals. Carbohydrate and cofactor-derived metabolites (e.g., gulonate, erythrocyte) were associated with cardiac dysfunction in euglycemic individuals. These cardiac dysfunction-related metabolites were prospectively associated with HF risk in the two glycemic groups (follow-up 7.5 years, 137 and 94 HF cases, per-SD increase hazard ratios range 1-1.9 and 1.1-2.9), respectively. HCHS/SOL results were consistent with those from ARIC. CONCLUSIONS: Metabolites known for microvascular complications were associated with cardiac dysfunction in hyperglycemic individuals but not among their euglycemic counterparts, supporting the premise that microvascular dysfunction contributes to HF pathogenesis in diabetes.
No takes yet. Share an insight, caveat, or question.
Yoshida et al. (2025) conducted an observational in Hyperglycemia and subclinical cardiac dysfunction (n=7,659). Microvascular disease-related metabolites vs. Euglycemic individuals was evaluated on Cardiac dysfunction and incident heart failure (HR range 1-1.9 and 1.1-2.9). Microvascular disease-related metabolites were associated with cardiac dysfunction and incident heart failure in hyperglycemic individuals (HR range 1-1.9 per-SD increase).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: